Eli Radiopharma Raises About $56M Series A for Radiopharmaceutical Cancer Drugs
Nearly RMB 400 million, about $56M, for a Hangzhou company that puts radioactive payloads on targeted drugs. Eli Radiopharma closed a Series A led by Huagai Capital, co-led by Bayland Capital, with Boyu Ventures, Delian Capital and others joining. Valuation was not disclosed. Release: https://www.prnewswire.com/news-releases/eli-radiopharma-completes-series-a-financing-of-nearly-rmb-400-million-to-advance-innovative-radiopharmaceutical-pipeline-toward-clinical-development-302933121.html
Radiopharmaceuticals, explained simply: a molecule that seeks out a specific target on cancer cells carries a radioactive isotope with it. Use a weak imaging isotope and you can see where the tumors are. Swap in a therapeutic isotope and the same molecule delivers radiation from inside. That pairing is called theranostics. Eli works on oncology and neurology programs in this space.
The money funds preclinical work, IND applications and early clinical trials, so this is a pipeline that has not reached patients yet.
Not an AI story, but it fits a wider pattern: China's biotech financing is coming back, and radioligand therapy is one of the hottest areas after big pharma paid up for the category in the past two years. At about $56M after currency conversion, this round sits just above our must-cover line.
← Back to all articles
Radiopharmaceuticals, explained simply: a molecule that seeks out a specific target on cancer cells carries a radioactive isotope with it. Use a weak imaging isotope and you can see where the tumors are. Swap in a therapeutic isotope and the same molecule delivers radiation from inside. That pairing is called theranostics. Eli works on oncology and neurology programs in this space.
The money funds preclinical work, IND applications and early clinical trials, so this is a pipeline that has not reached patients yet.
Not an AI story, but it fits a wider pattern: China's biotech financing is coming back, and radioligand therapy is one of the hottest areas after big pharma paid up for the category in the past two years. At about $56M after currency conversion, this round sits just above our must-cover line.
Comments